KFBIO and Zhejiang University Robotics Institute Launch Joint Innovation Center for Digital Pathology

Overview

To accelerate innovation in digital pathology, KFBIO (Ningbo Konfoong Bioinformation Tech Co., Ltd.) signed a strategic cooperation agreement with the Zhejiang University Robotics Institute on March 22.

Together, the two organizations established the Medical Image Processing Research and Development Center. This milestone strengthens the integration of artificial intelligence and digital pathology. More importantly, it creates a solid foundation for developing next-generation AI-powered pathology solutions through close industry-academia collaboration.

A Strategic Partnership for Innovation

The signing ceremony was hosted by Zhao Chuanping, Vice President of the Zhejiang University Robotics Institute.

Several representatives attended the event, including Lu Guodong, Executive Vice President of the institute, and Liu Bingxian, Chairman of KFBIO. Both leaders delivered keynote speeches during the ceremony. Xu Li, Vice President of the institute, and Wang Kehui, Vice General Manager of KFBIO, signed the cooperation agreement on behalf of their organizations.

Following the signing, Lu Guodong and Liu Bingxian jointly unveiled the plaque for the newly established Medical Image Processing Research and Development Center.

Driving Innovation in Digital Pathology

According to the cooperation agreement, both organizations will work closely on core technologies for digital pathology products.

Specifically, the partnership will focus on:

• Advancing digital pathology technologies
• Developing innovative AI-powered pathology solutions
• Cultivating professional talent
• Accelerating key technological breakthroughs

Ultimately, both parties aim to create a successful model for long-term collaboration between universities and industry partners in intelligent healthcare.

Three Strategic Goals

During the ceremony, Lu Guodong outlined three major objectives for the partnership.

First, the joint R&D center will serve as a platform for cultivating high-level professionals and researchers.

Second, it will support KFBIO’s long-term innovation strategy and business development.

Finally, the collaboration aims to establish a successful university-industry cooperation model that can be replicated across the intelligent healthcare sector.

Accelerating AI-Powered Pathology

Liu Bingxian emphasized that the partnership will create new opportunities for KFBIO in several important areas.

These include:

• Joint scientific research projects
• Professional talent development
• Integration of innovative resources
• High-level academic and technical exchanges

In addition, he noted that the collaboration will accelerate the research, development, and practical application of intelligent digital pathology solutions. This will further strengthen KFBIO’s innovation capabilities and support the future growth of AI-assisted pathology technologies.

Strengthening KFBIO’s Digital Pathology Ecosystem

This partnership marks another important step in KFBIO’s digital pathology strategy. Over the years, KFBIO has continued to invest in artificial intelligence and digital healthcare technologies.

Today, KFBIO is one of China’s leading providers of comprehensive digital pathology solutions. The company offers a complete product portfolio that includes:

• Digital pathology slide scanners
• AI-powered diagnostic solutions
• Pathology informatics platforms
• Routine laboratory equipment
• Diagnostic services

By combining its industrial expertise with the Zhejiang University Robotics Institute’s research capabilities, KFBIO aims to accelerate both technology innovation and product development.

As a result, new research findings can be translated into practical clinical applications more efficiently, bringing greater value to hospitals, laboratories, and patients.

Future Research Directions

Looking ahead, KFBIO and the Zhejiang University Robotics Institute will continue expanding their collaboration.

In particular, both organizations will focus on several key research areas, including:

• Pathological image analysis algorithms
• AI-assisted pathology diagnosis
• High-throughput slide scanning
• Advanced medical imaging technologies

Meanwhile, both teams will explore new opportunities to improve diagnostic efficiency, increase accuracy, and enhance workflow automation.

Ultimately, the partnership aims to build smarter and more efficient digital pathology solutions while supporting the digital transformation of the pathology industry.

Key Takeaways

The partnership between KFBIO and the Zhejiang University Robotics Institute represents a significant milestone in AI-driven digital pathology.

Key highlights include:

• KFBIO and the Zhejiang University Robotics Institute jointly established the Medical Image Processing Research and Development Center.
• The partnership combines academic research with industrial expertise to accelerate innovation in digital pathology.
• Both organizations will focus on AI-driven pathology solutions, talent development, and advanced technology research.
• Future projects will include pathological image analysis, AI-assisted diagnosis, and high-throughput imaging technologies.
• Together, the two organizations aim to improve diagnostic efficiency, promote intelligent healthcare, and accelerate the digital transformation of pathology.

Conclusion

The collaboration between KFBIO and the Zhejiang University Robotics Institute demonstrates a shared commitment to advancing digital pathology through innovation.

By integrating academic research with industry expertise, both organizations can accelerate the development of AI-powered pathology technologies and improve clinical applications.

Furthermore, the joint R&D center provides a strong platform for technology innovation, professional talent cultivation, and long-term research collaboration.

Looking ahead, KFBIO will continue working with leading research institutions to develop intelligent digital pathology solutions that improve diagnostic efficiency, support pathologists, and deliver better healthcare outcomes worldwide.